Progress on Tumor Infiltrating Lymphocytes in Immunotherapy and Prognosis Evaluation of Breast Cancer
-
摘要:
2020年女性乳腺癌已超越肺癌成为全球最常见的癌症，大量研究证实肿瘤浸润性淋巴细胞（TILs）对肿瘤具有杀伤力，并在识别肿瘤抗原中发挥重要作用，因此TILs在临床免疫治疗及乳腺癌预后评估中的应用受到广泛关注。本文综述了近期TILs在不同分子分型乳腺癌中的基础研究进展和临床应用现状，评估了TILs对乳腺癌预后评估及临床免疫治疗的价值。
Abstract:Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer in 2020. A large number of studies have proved that tumor infiltrating lymphocytes (TILs) are lethal to tumors and play an important role in identifying tumor antigens. Therefore, the application of TILs in clinical immunotherapy and prognosis assessment of breast cancer has attracted wide attention. In this review, the basic research progress and clinical application of TILs in different molecular types of breast cancer are reviewed, and the value of TILs in judging breast cancer prognosis and predicting the therapeutic effect of clinical immunotherapy is evaluated.
-
Key words:
- Breast cancer /
- Tumor infiltrating lymphocytes /
- Prognosis /
- Immunotherapy
-
Competing interests: The authors declare that they have no competing interests.作者贡献：洪晨忱：查阅资料，撰写论文姚峰：文章审阅及指导
-
[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2] Pilipow K, Darwich A, Losurdo A. T-cell-based breast cancer immunotherapy[J]. Semin Cancer Biol, 2021, 72: 90-101. doi: 10.1016/j.semcancer.2020.05.019
[3] Khan SY, Melkus MW, Rasha F, et al. Tumor-Infiltrating Lymphocytes (TILs) as a Biomarker of Abscopal Effect of Cryoablation in Breast Cancer: A Pilot Study[J]. Ann Surg Oncol, 2022, 29(5): 2914-2925. doi: 10.1245/s10434-021-11157-w
[4] Byrne A, Savas P, Sant S, et al. Tissue-resident memory T cells in breast cancer control and immunotherapy responses[J]. Nat Rev Clin Oncol, 2020, 17(6): 341-348. doi: 10.1038/s41571-020-0333-y
[5] Janssen A, Villacorta Hidalgo J, Beringer DX, et al. gammadelta T-cell Receptors Derived from Breast Cancer-Infiltrating T Lymphocytes Mediate Antitumor Reactivity[J]. Cancer Immunol Res, 2020, 8(4): 530-543. doi: 10.1158/2326-6066.CIR-19-0513
[6] Liu F, Hardiman T, Wu K, et al. Systemic immune reaction in axillary lymph nodes adds to tumor-infiltrating lymphocytes in triple-negative breast cancer prognostication[J]. NPJ Breast Cancer, 2021, 7(1): 86. doi: 10.1038/s41523-021-00292-y
[7] Denkert C, Von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy[J]. Lancet Oncol, 2018, 19(1): 40-50. doi: 10.1016/S1470-2045(17)30904-X
[8] Caparica R, Bruzzone M, Agostinetto E, et al. Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis[J]. Breast, 2021, 59: 183-192. doi: 10.1016/j.breast.2021.07.007
[9] Lai C, Coltart G, Shapanis A, et al. CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma[J]. J Immunother Cancer, 2021, 9(1): e001807. doi: 10.1136/jitc-2020-001807
[10] Kuroda H, Jamiyan T, Yamaguchi R, et al. Prognostic value of tumor-infiltrating B lymphocytes and plasma cells in triple-negative breast cancer[J]. Breast Cancer, 2021, 28(4): 904-914. doi: 10.1007/s12282-021-01227-y
[11] Wortman JC, He TF, Solomon S, et al. Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome[J]. NPJ Breast Cancer, 2021, 7(1): 84. doi: 10.1038/s41523-021-00291-z
[12] Kovács A, Stenmark Tullberg A, Werner Rönnerman E, et al. Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes: A Long-Term Follow-Up of the SweBCG91RT Randomized Trial[J]. J Clin Oncol, 2019, 37(14): 1179-1187. doi: 10.1200/JCO.18.02157
[13] Yeong J, Tan T, Chow ZL, et al. Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC[J]. J Clin Pathol, 2020, 73(9): 557-562. doi: 10.1136/jclinpath-2019-206252
[14] He J, Fu F, Wang W, et al. Prognostic value of tumour-infiltrating lymphocytes based on the evaluation of frequency in patients with oestrogen receptor-positive breast cancer[J]. Eur J Cancer, 2021, 154: 217-226. doi: 10.1016/j.ejca.2021.06.011
[15] Zhao S, Liu XY, Jin X, et al. Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer[J]. Theranostics, 2019, 9(17): 4935-4945. doi: 10.7150/thno.35730
[16] Kolberg-Liedtke C, Gluz O, Heinisch F, et al. Association of TILs with clinical parameters, Recurrence Score(R) results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial[J]. Breast Cancer Res, 2020, 22(1): 47. doi: 10.1186/s13058-020-01283-w
[17] Criscitiello C, Vingiani A, Maisonneuve P, et al. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer[J]. Breast Cancer Res Treat, 2020, 183(2): 347-354. doi: 10.1007/s10549-020-05771-7
[18] Wang K, Xu J, Zhang T, et al. Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis[J]. Oncotarget, 2016, 7(28): 44288-44298. doi: 10.18632/oncotarget.9988
[19] Mao Y, Qu Q, Zhang Y, et al. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis[J]. PLoS One, 2014, 9(12): e115103. doi: 10.1371/journal.pone.0115103
[20] Li J, Jiang Z. Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification[J]. Cancer Biol Med, 2022. Online ahead of print.
[21] Van Bockstal MR, Cooks M, Nederlof I, et al. Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group[J]. Cancers (Basel), 2021, 13(19): 4910. doi: 10.3390/cancers13194910
[22] Voorwerk L, Slagter M, Horlings HM, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial[J]. Nat Med, 2019, 25(6): 920-928. doi: 10.1038/s41591-019-0432-4
[23] Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial[J]. Lancet, 2020, 396(10265): 1817-1828. doi: 10.1016/S0140-6736(20)32531-9
[24] Emens LA, Molinero L, Loi S, et al. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study[J]. J Natl Cancer Inst, 2021, 113(8): 1005-1016. doi: 10.1093/jnci/djab004
[25] Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, et al. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice[J]. J Pathol, 2020, 250(5): 667-684. doi: 10.1002/path.5406
[26] Gradishar WJ, Moran MS, Abraham J, et al. NCCN Guidelines® Insights: Breast Cancer, Version 4.2021[J]. J Natl Compr Canc Netw, 2021, 19(5): 484-493. doi: 10.6004/jnccn.2021.0023
[27] Rosenbaum SR, Wilski NA, Aplin AE. Fueling the Fire: Inflammatory Forms of Cell Death and Implications for Cancer Immunotherapy[J]. Cancer Discov, 2021, 11(2): 266-281. doi: 10.1158/2159-8290.CD-20-0805
[28] Zacharakis N, Chinnasamy H, Black M, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer[J]. Nat Med, 2018, 24(6): 724-730. doi: 10.1038/s41591-018-0040-8
[29] Venetis K, Invernizzi M, Sajjadi E, et al. Cellular immunotherapy in breast cancer: The quest for consistent biomarkers[J]. Cancer Treat Rev, 2020, 90: 102089. doi: 10.1016/j.ctrv.2020.102089
[30] Lee HJ, Kim YA, Sim CK, et al. Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer[J]. Oncotarget, 2017, 8(69): 113345-113359. doi: 10.18632/oncotarget.23007
-
期刊类型引用(2)
1. 王海宏，宋玉，贺凡，杨兵，唐东昕，吴文宇. 基于伏邪理论探讨循环肿瘤细胞与结直肠癌复发转移的相关性. 中医杂志. 2024(19): 1983-1987 . 
百度学术
2. 阙祖俊，田建辉. 根除休眠播散肿瘤细胞防止肿瘤转移的潜在治疗药物的研究进展. 中国肿瘤生物治疗杂志. 2024(11): 1146-1151 . 百度学术
其他类型引用(0)
计量
- 文章访问数: 2878
- HTML全文浏览量: 610
- PDF下载量: 1446
- 被引次数: 2
下载:
